The overall results indicated that polymorphism T>C of rs1058</span>205 was associated with decreased risk of PCa</span> (allele contrast: OR = 0.75, 95% CI = 0.64-0.88, <i>P</i><sub>heterogeneity</sub> < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.42-0.81, <i>P</i><sub>heterogeneity</sub> < 0.001), particularly in Caucasian population (allele contrast: OR = 0.77, 95% CI = 0.65-0.91, <i>P</i><sub>heterogeneity</sub> < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.41-0.82, <i>P</i><sub>heterogeneity</sub> < 0.001).
The rs61752561 SNP appears to have a potential role in PCa pathogenesis by changing the glycosylation, protein stability, and PSA activity and may also affect the clinically measured F/T PSA ratio.
Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (<i>KLK3</i>) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (<i>P</i> = 2.3 × 10<sup>-8</sup>).